SCHEMBL25375484

SCHEMBL25375484

NC(=O)C(=O)N(Cc1ccccc1)Cc1cccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
MC4R P32245 4/20 0.49
MC5R P33032 4/20 0.49
MC1R Q01726 4/20 0.49
MC3R P41968 3/20 0.48
CFTR P13569 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
METAP2 P50579 1/20 0.47
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
MTNR1A P48039 1/20 0.44
PDK1 Q15118 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28402183 0.93 CYP1A2 (0.51) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL25378150 0.88 HDAC1 (0.46) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL25376490 0.84 CYP1A2 (0.50) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL6682858 0.83 LMNA (0.53) TDP1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL25377644 0.80 HDAC1 (0.50) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL25375583 0.80 ALDH1A1 (0.45) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL25378271 0.79 TAS2R14 (0.47)
SCHEMBL25377537 0.79 TSHR (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4015499 0.79 MAPT (0.54) HDAC1HDAC6MC4RMC5RMC1R
SCHEMBL4015503 0.79 MAPT (0.54) HDAC1HDAC6MC4RMC5RMC1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 HDAC1 1336/4885HDAC6 839/4885MC4R 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.